Anx-131 | __top__

To understand ANX-131, you must understand the GABA-A receptor. Think of it as the brain’s "brake pedal." When activated, it calms neuronal firing.

Based on published patent data (WO2023/154321) and preclinical posters from the 2024 ACNP (American College of Neuropsychopharmacology) annual meeting, here is what we know: ANX-131

To understand the importance of a compound like ANX-131, one must first understand the context of its origin. For decades, the pharmaceutical industry relied on high-throughput screening (HTS), where millions of existing compounds were tested against a biological target to find a hit. While effective, HTS often leads to "molecular obesity"—compounds that are too large, too lipophilic, and poorly soluble. To understand ANX-131, you must understand the GABA-A

Critics argue this is insufficient. If a bad actor gains access to the magnetic induction link, they could theoretically induce phantom sensations (paresthesia) or erase motor memories. The developers have responded by requiring galvanic body response (skin conductance) as a second-factor authentication for any firmware update. If a bad actor gains access to the

Many modern cancer drugs work by inhibiting kinases—enzymes that act as switches for cell growth. The structure of ANX-131 aligns well with the ATP-binding pockets common to many kinases. Researchers are currently exploring derivatives of ANX-131 as selective inhibitors for hard-to-target cancers, potentially offering treatments for tumors that have developed resistance to first-generation therapies.